A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols

Marley, Richard; Feelisch, Martin; Holt, Stephen; Moore, Kevin

doi:10.1080/10715760000300011

Cited by 155 publications

(111 citation statements)

References 21 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…The disadvantage of this method for the determination of nitrite is that it measures both nitrite and S-nitrosothiols. Marley et al [31] measured plasma RSNOs using Cu(1)/ KI/I 2 reagents after removing the nitrite with acidified sulfanilamide, which forms a diazonium complex that does not generate a chemiluminescence signal. Subsequent studies [32] have shown that the I 3 -reductive chemiluminescence assay also releases NO from RNNOs of plasma.…”

Section: Discussionmentioning

confidence: 99%

Measurement of plasma nitrite by chemiluminescence without interference of S-, N-nitroso and nitrated species

Nagababu

Rifkind

2007

Free Radical Biology and Medicine

View full text Add to dashboard Cite

Recent studies have demonstrated that plasma nitrite (NO 2 -) reflects endothelial nitric oxide synthase activity and it has been proposed as a prognostic marker for cardiovascular disease. In addition, NO 2 -itself has been shown to have biological activities thought to be triggered by reduction back to NO in blood and tissues. The development of sensitive and reproducible methods for the quantitative determination of plasma NO 2 -is, therefore, of great importance. Ozone-based chemiluminescence assays have been shown to be highly sensitive for the determination of nanomolar quantities of NO and NO related species in biological fluids. We report here an improved direct chemiluminescence method for the determination of plasma NO 2 -without interference of other nitric oxide related species such as nitrate, S-nitrosothiols, N-nitrosamines, nitrated proteins and nitrated lipids. The method involves a reaction system consisting of glacial acetic acid and ascorbic acid in the purge vessel of the NO analyzer. Under these acidic conditions NO 2 -is stoichiometrically reduced to NO by ascorbic acid. Fasting human plasma NO 2 -values were found in the range of 56-210 nM (mean =110 ± 36 nM). This method has high sensitivity with an accuracy of 97% and high precision (C.V <10%) for determination of plasma nitrite. The present method is simple and highly specific for plasma NO 2 -. It is particularly suited to evaluate vasculature endothelial NO production that predicts the risks for cardiovascular disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Measurement of plasma nitrite by chemiluminescence without interference of S-, N-nitroso and nitrated species

Nagababu

Rifkind

2007

Free Radical Biology and Medicine

View full text Add to dashboard Cite

show abstract

“…As a candidate for creating such a NO traffic protein, we selected human serum albumin (HSA), because HSA has high biocompatibility and good biodegradability, and because 'endogenous' S-nitrosothiols in serum are largely related to HSA. 13,14) Endogenous HSA has one Snitrosated site at Cys-34 thiol. The endogenous S-nitrosated HSA (SNO-HSA) was named 'Mono-SNO-HSA,' which has significantly superior stability compared with low molecular weight (LMW) S-nitrosothiols.…”

Section: Human Serum Albumin As the Key Play-er In The Nitric Oxide Tmentioning

confidence: 99%

Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers

Ishima

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Biomacromolecules (>40 kDa) have been developed as drug delivery system (DDS) carriers of low-molecular weight drugs to promote these drugs' uptake by cancer tissues via enhanced permeability and retention (EPR) effects. Human serum albumin (HSA) has been found to accumulate in cancer tissues via this EPR effect. HSA is the most abundant protein in serum, which performs essential physiological functions such as the transportation of many endogenous and exogenous ligands. Nitric oxide (NO) is a very small ligand of HSA; it is a unique and diffusible molecular messenger that plays a central role in mammalian physiology. Key words human serum albumin; nitric oxide; S-nitrosation; drug delivery system; anticancer activity; enhanced permeability and retention effect HUMAN SERUM ALBUMIN AS THE KEY PLAY-ER IN THE NITRIC OXIDE TRAFFIC SYSTEM IN HUMANSA gas modulator, nitric oxide (NO), plays an important role in the human body.1-7) A small amount of NO is synthesized by endothelial and neuronal NO synthases. Its actions, including the relaxation of vascular smooth muscle, are pleiotropic. 8,9) However, NO can sometimes be cytotoxic. For instance, a large amount of NO inhibits the growth of cancer cells and induces cell death via apoptosis. 10,11) Many studies have identified that the apoptosis of cancer cells (directly) and the inhibition of cancer progression (indirectly) have relevance to NO.12) Unfortunately, the T 1/2 of NO is so extremely short (<5 s) that NO without a carrier cannot be applied as a therapeutic biological agent. Thus, NO releasing compounds with pharmacological activity have been synthesized around the world.For a long-acting and safe NO donor, we examined the possibility of developing a 'NO traffic protein' as a superior NO carrier. This 'NO traffic protein' would include (1) a NO binding protein with the superior efficiency of S-nitrosation, (2) superior stability of the S-nitroso form in human blood, and (3) the superior efficiency of NO transfer in selected cells which require NO. As a candidate for creating such a NO traffic protein, we selected human serum albumin (HSA), because HSA has high biocompatibility and good biodegradability, and because 'endogenous' S-nitrosothiols in serum are largely related to HSA. 13,14) Endogenous HSA has one Snitrosated site at Cys-34 thiol. The endogenous S-nitrosated HSA (SNO-HSA) was named 'Mono-SNO-HSA,' which has significantly superior stability compared with low molecular weight (LMW) S-nitrosothiols.

show abstract

“…The NOx content in plasma and tissues was determined on calibration curves prepared by adding known amounts of sodium nitrate to blank plasma or tissue homogenates in the concentration range 0.5-100 AM and expressed as AM and nmoles/g wet tissue respectively. RS-NO were determined by a copper(I)/iodide/iodine-mediated cleavage of RS-NO to form NO (Marley et al, 2000), which was quantified by its chemiluminescent reaction in gas phase with ozone. The reaction chamber containing 4 ml glacial acetic acid and 1 ml potassium iodide (50 mg/ml) was kept at 70 jC via a water jacket.…”

Section: Ozone-based Chemilumiscent Determination Of Plasma and Tissumentioning

confidence: 99%

Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat

et al. 2004

View full text Add to dashboard Cite

The metabolic fate of nitric oxide (NO) released from nitroaspirin, benzoic acid, 2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), the lead compound of a new class of NO-releasing non steroidal anti-inflammatory drugs (NO-NSAIDs), has been studied in the rat following p.o. and i.p. administration of 100 mg/kg, by monitoring in plasma the bioactive storage forms of NO (S-nitrosothiols, RS-NO) and its oxidation products (nitrites/nitrates, NOx) by a chemiluminescent assay. In parallel, plasma was analyzed for unchanged drug and metabolites by reverse-phase HPLC. In orally treated rats, no unchanged drug is observed in the 0 -24 h interval post-dosing, but only salicylic acid (SA), NOx and RS-NO. The time-course of SA formation parallels that of plasma NOx (plateau after 6 h). Nitrosothiols in plasma are detectable at 1 h, peak at 4 h postadministration, and decline thereafter. The results relative to i.p. administration show a more pronounced and rapid NO delivery (peak of both NOx and RS-NO at 1 h and plateau between 1 and 2 h), still coincident with the peak of SA, and the presence in plasma of NCX 4015 (a metabolite of NCX 4016 which still bears the nitrate function). In myocardial tissue from p.o. treated rats, no drug or metabolites were ever detected, and the NOx levels were always in the range of the controls. Conversely, following i.p. treatment, we observed a rapid compartmentalization within the heart of the unchanged drug, which rapidly disappears in favour of its breakdown products NCX 4015 and SA, with a concomitant rise in myocardial NOx levels up to 2 h. To check the stability of NCX 4016 in the acidic gastric milieu and to explain the different distribution of the drug following p.o. or i.p. administration, the gastric content of the orally-treated animals at different post-dosing times was analysed by HPLC. The unchanged drug was detected up to 8 h post-dosing (levels slowly decreased with time), and the only metabolite to be detected was the O-deacetylated derivative (NCX 4023), which was present in low concentrations up to 4 h post-dosing. This indicates that NCX 4016 does not undergo biotransformation in the upper part of gastrointestinal tract (no direct release of NO in this district) and that the stomach acts as a reservoir for the drug.

show abstract

A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols

Cited by 155 publications

References 21 publications

Measurement of plasma nitrite by chemiluminescence without interference of S-, N-nitroso and nitrated species

Measurement of plasma nitrite by chemiluminescence without interference of S-, N-nitroso and nitrated species

Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers

Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat

Contact Info

Product

Resources

About